Monday, April 29, 2024

Vogon Today

Selected News from the Galaxy

StartMag

What happens to the Astrazeneca-Irbm vaccine?

3 years ago babelfish

What happens to the Astrazeneca-Irbm vaccine?

At the moment there is "insufficient information even to give a conditional green light to commercialization", said EMA's deputy executive director, Npel Wathion, on the Astrazeneca-Oxford-Irbm vaccine.

In the war on Covid-19 a single weapon is not enough. More drugs are needed. On January 6, the approval of Moderna's vaccine should arrive which, like that of Pfizer already approved and distributed, is based on the mRna platform, but it will be necessary to wait at least February for the EMA to authorize the Astrazeneca vaccine (of which Italy has optioned 40 million doses).

There are information "also insufficient to give a conditional green light to commercialization," said the Deputy Executive Director of ' Ema , Npel Wathion.

All the details.

ASTRAZENECA: APPROVAL IN JANUARY?

Let's start with the plans of the EMA. The European Medicines Agency's approval of the Covid-19 vaccine developed by the University of Oxford in collaboration with the Italian Irbm and produced by Astrazeneca may not arrive by the end of January. This was said by the agency's deputy executive director in an interview with the Belgian newspaper Het Nieuwsblad .

"The application has not yet been presented", added the deputy director, arguing that there is still information on the vaccine "insufficient even to give a conditional green light to marketing".

FURTHER DATA EXPECTED

"More data and information on the quality of the vaccine is needed, and after that, the company must submit a formal application for approval," said Wathion, saying it is "unlikely" to get a green light next month.

HOPE HOPES APPROVAL AS SOON AS BEFORE

The news will not please Roberto Speranza, the Minister of Health hoped for a quick approval of the Astrazeneca vaccine to be able to vaccinate as many citizens as possible by March.

“According to the contract plan, in the first quarter we should receive 8.7 million doses produced by Pfizer and 1.3 million produced by Moderna. Total, 10 million doses, corresponding to 5 million people vaccinated, given that with a booster you need two doses per person. If AstraZeneca also reaches the finish line immediately, another 16 million doses will be added within the first quarter, corresponding to another 8 million vaccinated people. Final result: as early as April 1st we could have 13 million vaccinated, and so we would have already reached Phase One, that is, the one that allows us to have the first epidemiological impact ”, said Speranza in an interview with La Stampa.

ITALY: 40 MILLION DOSES OPTIONED

The Astrazeneca vaccine, on the other hand, is the workhorse on which the Italian government has focused since the early stages of experimentation, optioning 40 million doses.

95% EFFECTIVENESS FOR ASTRAZENECA VACCINE

And if it is true that the complete dossier has not yet landed on the EMA tables, it is also true that Astrazeneca seems to have reached a small milestone: the one that sees the effectiveness rise to 95%.

THE ANNOUNCEMENT OF SORIOT, CEO OF ASTRAZENECA

At least according to the announcements of Pascal Soriot, CEO of Astrazeneca: "Following the latest additional tests, we can say that our vaccine also develops immunity in 95% of cases, equal to that of Pfizer", Soriot told the Sunday Times .

A TRAVELED PATH

Words to be verified with the data. The path of the Astrazeneca vaccine, we cannot hide it, has been quite troubled. After a stop for a suspected adverse reaction, the vaccine recorded an estimated efficacy of 75% as an average value and approximately 90% when administered first with a half dose and then a full dose after three weeks.

AT THE STUDIO EXPERIMENTATION WITH SPUTNIK

To try to increase the percentage, Astrazeneca has also started a combined trial with the Russian Sputnik V vaccine (they are both created on the basis of adenoviral vectors). And the choice, at least in theory, is to be promoted: "the memory cells as a result of using such a two-component hybrid vaccine will be much better formed, and the vaccine, of course, will protect the vaccinated not for three or four months. , but at least for two years, ” said Alexander Ginzburg, director of the Gamaleya Center, broadcast on the Rossiya 24 television channel.

Practical results are now awaited.

This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/che-cosa-succede-al-vaccino-astrazeneca-irbm/ on Tue, 29 Dec 2020 15:42:54 +0000.